DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20214152

A study of efficacy of ‘rota virus vaccination’ on morbidity due to rotavirus diarrhoea in children aged 6 months to 5 years

Shreya Agrawal, Deepak Ugra

Abstract


Background: Rotavirus diarrhoea was the most common cause of mortality due to diarrhoea among children under 5 years of age. Deaths due to diarrhoea is one of important health issue that needs to be addressed due to high morbidity and mortality associated with it. Rotavirus is recognized as the major cause of hospitalizations among children and it is clear that improvements in hygiene and sanitation alone are not sufficient       to decrease the cases. This study was conducted to assess the efficacy of rotavirus vaccine on morbidity amongst vaccinated and unvaccinated children.

Methods: Our study include 40 patients diagnosed with diarrhoea, with stool report positive for rotavirus, with varying degree of dehydration coming to Lilavati Hospital in outpatient department, pediatric ward or pediatric intensive care unit.

Results: Out of 40 children, 77.5% of the children vaccinated. We observed the rate of hospitalization was higher 77.8% i.e. 7/9 in the group of unvaccinated children than 45.2% i.e. 14/31 in group of vaccinated children. We found significant difference in the degree of dehydration in vaccinated and unvaccinated children. We found that nearly half of the children in vaccinated group did not have signs of dehydration (belongs to no dehydration category as per World Health Organization scale), while more than 88% of the children in unvaccinated group had some (66.7%) to severe (22.2%) degree of dehydration.

Conclusions: Our study concludes that vaccination against rotavirus significantly reduce the morbidity associated with rotavirus diarrhoea as compared to unvaccinated children.


Keywords


Diarrhoea, Rotavirus, Rotavirus vaccine, Morbidity

Full Text:

PDF

References


Sanderson C, Clark A, Taylor D, Bolanos B. Global review of rotavirus morbidity and mortality data by age and region. Rep to WHO/IVB. 2011;1-42.

Parashar UD, Hummelman EG, Bresee JS, Miller MA. Rotavirus-Associated Deaths. Emerg Infect Dis. 2003;9(5):565-72.

Soares-Weiser K, MacLehose H, Bergman H, Ben-Aharon I, Nagpal S, Goldberg E, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2012;(2).

Burnett E, Tate JE, Kirkwood CD, Nelson EAS, Steele AD, Parashar UD. Estimated Impact of Rotavirus Vaccine on Hospitalizations and Deaths from Rotavirus Diarrhea among Children <5 in Asia. Expert Rev Vaccines. 2019;17(5):453-60.

Burnett E, Jonesteller CL, Tate JE, Yen C, Parashar D. Rotavirus Vaccines: Effectiveness, Safety and Future Directions. Paediatr Drugs. 2018;215(11):1666-72.

Ngabo F, Tate JE, Gatera M, Rugambwa C, Donnen P, Lepage P, et al. Effect of pentavalent rotavirus vaccine introduction on hospital admissions for diarrhoea and rotavirus in children in Rwanda : a time-series analysis. Lancet Glob Heal. 2008;4(2):129-36.

Araki K, Hara M, Tsugawa T, Shimanoe C, Nishida Y, Matsuo M, et al. Effectiveness of monovalent and pentavalent rotavirus vaccines in Japanese children. Vaccine. 2018;36(34):5187-93.